These innovative molecules represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in controlling blood glucose levels. Trizepatide, on the other hand, targets all three incretin receptors – GLP-1